Guggenheim raised the firm’s price target on Insmed (INSM) to $172 from $125 and keeps a Buy rating on the shares as a result of updates that include increasing its Brinsupri non-cystic fibrosis bronchiectasis revenue estimates, adding revenue estimates for TPIP in IPF, and decreasing its terminal decline rate given added confidence on the long-term potential of the company’s pipeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Strategic Advancements and Market Potential: A Buy Recommendation
- Optimistic Buy Rating for Insmed: TPIP’s Potential in the IPF Market
- Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity
- Insmed’s Growth Potential Highlighted by TPIP’s Market Opportunity and Positive Outlook
- Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development